18 June Should we stop aspirin prophylaxis in pregnant women diagnosed with COVID-19?
M. Gavillet, DL Rolnik, MK Hoffman, A. Panchaud and D. Baud
ABSTRACT
Prophylactic administration of low doses of aspirin to pregnant women is common. It is currently indicated in those women with moderate to high risk of preeclampsia, a group that represents 10 to 15% of all pregnancies.
While we support the continued use of prophylactic aspirin in pregnant women during the COVID‐19 pandemic, which is consistent with views recently expressed by Kwiatkowski et al; In this magazine, our opinion is more nuanced. We recommend immediate cessation of aspirin prophylaxis prescribed for preeclampsia upon diagnosis of SARS-CoV-2 infection, avoidance of aspirin during illness, and resumption of medication after complete recovery, especially in women in the third trimester of pregnancy. as the benefit of aspirin is minimal and could contribute to severe bleeding in thrombocytopenic patients with COVID-19 or if maternal condition indicates emergency cesarean delivery.